Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD.
暂无分享,去创建一个
Feng Zhu | Weiwei Xue | Xiaojun Yao | Guoxun Zheng | Tingting Fu | Yuzong Chen | Yuzong Chen | X. Yao | Weiwei Xue | Fengyuan Yang | Panpan Wang | Guoxun Zheng | Feng Zhu | Tingting Fu | Xiaoyu Zhang | Fengyuan Yang | Panpan Wang | Xiaoyu Zhang | Feng-yuan Yang | Guo-xun Zheng
[1] M. Reith,et al. Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template. , 2015, Bioorganic & medicinal chemistry.
[2] J. Buitelaar,et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. , 2013, Journal of child psychology and psychiatry, and allied disciplines.
[3] M. Rosales-Hernández,et al. Current Tools and Methods in Molecular Dynamics (MD) Simulations for Drug Design. , 2016, Current medicinal chemistry.
[4] S. Sinning,et al. Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters. , 2012, ACS chemical neuroscience.
[5] Sunhwan Jo,et al. CHARMM‐GUI Membrane Builder toward realistic biological membrane simulations , 2014, J. Comput. Chem..
[6] M. Reith,et al. The Atypical Stimulant and Nootropic Modafinil Interacts with the Dopamine Transporter in a Different Manner than Classical Cocaine-Like Inhibitors , 2011, PloS one.
[7] J. Enders,et al. Improved Chiral Separation of Methamphetamine Enantiomers Using CSP-LC-MS-MS. , 2016, Journal of analytical toxicology.
[8] Feng Zhu,et al. Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks , 2016, BioMed research international.
[9] E. Gouaux,et al. Neurotransmitter and psychostimulant recognition by the dopamine transporter , 2015, Nature.
[10] B. Kirtman,et al. Efficient vector potential method for calculating electronic and nuclear response of infinite periodic systems to finite electric fields. , 2007, The Journal of chemical physics.
[11] L. Briars,et al. A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder. , 2016, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.
[12] C. Simmerling,et al. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.
[13] Cheng Zhang,et al. Nature's contribution to today's pharmacopeia , 2014, Nature Biotechnology.
[14] Philip C Biggin,et al. Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations , 2016, Journal of the American Chemical Society.
[15] S. Sinning,et al. Comparative modeling of the human monoamine transporters: similarities in substrate binding. , 2013, ACS chemical neuroscience.
[16] M. Rutkowski,et al. Phosphorylation of acyclonucleosides by nucleoside phosphotransferase from higher plants and bacteria. , 1991, Acta biochimica Polonica.
[17] Weiwei Xue,et al. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective , 2016, PloS one.
[18] A. S. Mackenzie. MOBILITY OF MEDICAL MANPOWER , 1976, The Lancet.
[19] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[20] H. E. Rosvold,et al. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. , 1979, Science.
[21] P A Kollman,et al. Structure and thermodynamics of RNA-protein binding: using molecular dynamics and free energy analyses to calculate the free energies of binding and conformational change. , 2000, Journal of molecular biology.
[22] B. Schiøtt,et al. Identification of a common binding mode for imaging agents to amyloid fibrils from molecular dynamics simulations. , 2013, Journal of the American Chemical Society.
[23] C. Goldberger,et al. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder , 2015, Current medical research and opinion.
[24] A. Sandelin,et al. Interaction of Antidepressants with the Serotonin and Norepinephrine Transporters , 2012, The Journal of Biological Chemistry.
[25] Feng Zhu,et al. Differentiating Physicochemical Properties between Addictive and Nonaddictive ADHD Drugs Revealed by Molecular Dynamics Simulation Studies. , 2017, ACS chemical neuroscience.
[26] Youyong Li,et al. Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models. , 2013, The journal of physical chemistry. B.
[27] Feng Xu,et al. Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. , 2015, Pharmacological research.
[28] F. Castellanos,et al. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes , 2002, Nature Reviews Neuroscience.
[29] R. Freyberg,et al. Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain , 2016, Nature Communications.
[30] J. Bibb,et al. Attention-Deficit/Hyperactivity Phenotype in Mice Lacking the Cyclin-Dependent Kinase 5 Cofactor p35 , 2010, Biological Psychiatry.
[31] Feng Zhu,et al. Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study , 2016, Scientific Reports.
[32] Feng Zhu,et al. Performance Evaluation and Online Realization of Data-driven Normalization Methods Used in LC/MS based Untargeted Metabolomics Analysis , 2016, Scientific Reports.
[33] Miss A.O. Penney. (b) , 1974, The New Yale Book of Quotations.
[34] P. Wakeley,et al. Synthesis , 2013, The Role of Animals in Emerging Viral Diseases.
[35] A. Narkpongphun,et al. Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials , 2015, Drug design, development and therapy.
[36] M. Liechti,et al. Pharmacological characterization of designer cathinones in vitro , 2013, British journal of pharmacology.
[37] Bo Li,et al. NOREVA: normalization and evaluation of MS-based metabolomics data , 2017, Nucleic Acids Res..
[38] Gábor J. Székely,et al. Hierarchical Clustering via Joint Between-Within Distances: Extending Ward's Minimum Variance Method , 2005, J. Classif..
[39] A. Altamura,et al. The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects , 2011, CNS neuroscience & therapeutics.
[40] Tingjun Hou,et al. Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. , 2014, Physical chemistry chemical physics : PCCP.
[41] Ben M. Webb,et al. Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.
[42] Tingjun Hou,et al. P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape , 2014, PLoS Comput. Biol..
[43] Sylvia Tippmann,et al. Programming tools: Adventures with R , 2014, Nature.
[44] Jahan B. Ghasemi,et al. Computer‐aided drug design to explore cyclodextrin therapeutics and biomedical applications , 2017, Chemical biology & drug design.
[45] Xiao Hua Ma,et al. Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs , 2012, PloS one.
[46] K. Perry,et al. Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder , 2002, Neuropsychopharmacology.
[47] Shuang Li,et al. SVM-Prot 2016: A Web-Server for Machine Learning Prediction of Protein Functional Families from Sequence Irrespective of Similarity , 2016, PloS one.
[48] Dan Li,et al. Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies. , 2016, Physical chemistry chemical physics : PCCP.
[49] Eric Gouaux,et al. X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine , 2015, Nature Structural &Molecular Biology.
[50] R. Blakely,et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.
[51] Jacob Andersen,et al. Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter , 2015, Scientific Reports.
[52] Märtha Sund-Levander,et al. Assessment of body temperature measurement options. , 2013, British journal of nursing.
[53] L. Guo,et al. Construction and structural modeling of a single-chain Fv-asparaginase fusion protein resistant to proteolysis. , 2000, Biotechnology and bioengineering.
[54] B. Tidor,et al. Rational Approaches to Improving Selectivity in Drug Design , 2012, Journal of medicinal chemistry.
[55] B. Ploeger,et al. Estimation of binding rate constants using a simultaneous mixed‐effects method: application to monoamine transporter reuptake inhibitor reboxetine , 2010, British journal of pharmacology.
[56] Peer Bork,et al. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation , 2007, Bioinform..
[57] B. Schiøtt,et al. Ligand Induced Conformational Changes of the Human Serotonin Transporter Revealed by Molecular Dynamics Simulations , 2013, PloS one.
[58] Rodrigo Lopez,et al. Clustal W and Clustal X version 2.0 , 2007, Bioinform..
[59] A. Yan,et al. Aurora-A kinase inhibitor scaffolds and binding modes. , 2011, Drug discovery today.
[60] Feng Zhu,et al. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. , 2016, Physical chemistry chemical physics : PCCP.
[61] Sequence analysis and homology modeling of peroxidase from Medicago sativa , 2012, Bioinformation.
[62] A. Arnsten,et al. Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions , 2004, Biological Psychiatry.
[63] M. Reith,et al. Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate‐binding sites in a single transporter , 2010, Journal of neurochemistry.
[64] Jia Zhou. Norepinephrine transporter inhibitors and their therapeutic potential. , 2004, Drugs of the future.
[65] Martti T Tammi,et al. What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets , 2009, Journal of Pharmacology and Experimental Therapeutics.
[66] R. Lukas,et al. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. , 2009, Journal of medicinal chemistry.
[67] S. Genheden,et al. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.
[68] Akbar Nayeem,et al. A comparative study of available software for high‐accuracy homology modeling: From sequence alignments to structural models , 2006, Protein science : a publication of the Protein Society.
[69] Weiliang Zhu,et al. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation , 2015, Scientific Reports.
[70] Jörg Weiser,et al. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999, J. Comput. Chem..
[71] Tingjun Hou,et al. Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..
[72] Lin Shi,et al. Large-scale untargeted LC-MS metabolomics data correction using between-batch feature alignment and cluster-based within-batch signal intensity drift correction , 2016, Metabolomics.
[73] M. Frank,et al. From reinforcement learning models to psychiatric and neurological disorders , 2011, Nature Neuroscience.
[74] Yang Song,et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..
[75] C. Kilts,et al. Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter. , 2009, Journal of medicinal chemistry.
[76] V. Hornak,et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.
[77] Lu Huang,et al. Update of TTD: Therapeutic Target Database , 2009, Nucleic Acids Res..
[78] Tingjun Hou,et al. Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches , 2013, J. Chem. Inf. Model..
[79] N. Volkow,et al. The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. , 2014, JAMA psychiatry.
[80] F. Castellanos,et al. Childhood Attention-Deficit/Hyperactivity Disorder and Homelessness: A 33-Year Follow-Up Study. , 2016, Journal of the American Academy of Child and Adolescent Psychiatry.
[81] Dan Li,et al. Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking. , 2016, Physical chemistry chemical physics : PCCP.
[82] P. Kollman,et al. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .
[83] Dan J Stein,et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.
[84] Feng Zhu,et al. Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters , 2017 .
[85] Lin Tao,et al. Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting , 2011, Proceedings of the National Academy of Sciences.
[86] B Xie,et al. Trends in the exploration of anticancer targets and strategies in enhancing the efficacy of drug targeting. , 2008, Current molecular pharmacology.
[87] Kyeong-Man Kim,et al. Exploration of substituted arylpiperazine-tetrazoles as promising dual norepinephrine and dopamine reuptake inhibitors. , 2016, Bioorganic & medicinal chemistry.
[88] Benjamin D. Madej,et al. Lipid14: The Amber Lipid Force Field , 2014, Journal of chemical theory and computation.
[89] K. Patrick,et al. Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity , 2007, Behavioural pharmacology.
[90] W. C. Still,et al. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999 .
[91] C. Vasavi,et al. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations. , 2017, Journal of molecular graphics & modelling.
[92] Ying Yang,et al. Molecular Dynamics Simulation and Free Energy Calculation Studies of the Binding Mechanism of Allosteric Inhibitors with p38α MAP Kinase , 2011, J. Chem. Inf. Model..
[93] F. Tarazi,et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB‐1020: Implications for treatment of attention‐deficit hyperactivity disorder , 2012, Synapse.
[94] G. Madhavi Sastry,et al. Homology modeling of membrane proteins: A critical assessment , 2006, Comput. Biol. Chem..
[95] S. Faraone,et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder , 2005, Biological Psychiatry.
[96] Feng Xu,et al. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information , 2015, Nucleic Acids Res..
[97] H. Sitte,et al. Probing the Selectivity of Monoamine Transporter Substrates by Means of Molecular Modeling , 2013, Molecular informatics.
[98] Eric J. Nestler,et al. The molecular neurobiology of depression , 2008, Nature.
[99] H. Navarro,et al. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. , 2009, Journal of medicinal chemistry.
[100] Ben M. Webb,et al. Comparative Protein Structure Modeling Using MODELLER , 2007, Current protocols in protein science.
[101] Torsten Schwede,et al. BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .
[102] Stefan Johansson,et al. Multicenter Analysis of the SLC6A3/DAT1 VNTR Haplotype in Persistent ADHD Suggests Differential Involvement of the Gene in Childhood and Persistent ADHD , 2010, Neuropsychopharmacology.
[103] Feng Zhu,et al. Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods. , 2015, Bio-medical materials and engineering.
[104] Zhen Yan,et al. Methylphenidate Exerts Dose-Dependent Effects on Glutamate Receptors and Behaviors , 2014, Biological Psychiatry.